EU’s CHMP Gives Nod To First Biosimilar Epoetin Alfa Formulations
This article was originally published in The Pink Sheet Daily
Executive Summary
Sandoz is set to launch its biosimilar, Binocrit, in 2007 following commission approval, the firm tells “The Pink Sheet” DAILY.
You may also be interested in...
Insmed Takes Follow-On Biologics Push To The Web
Not enough understanding of debate, says Insmed exec; economic study to come
Insmed Takes Follow-On Biologics Push To The Web
Not enough understanding of debate, says Insmed exec; economic study to come
Amgen’s European EPO Sales Unaffected By Biosimilars – For Now
European biosimilars competing against first-generation erythropoietins, Amgen notes during Q3 earnings call.